CONTEXT: Large increases in systemic free fatty acid (FFA) availability in the absence of a corresponding increase in fatty acid oxidation can create a host of metabolic abnormalities. These adverse responses are thought to be the result of fatty acids being shunted into hepatic very low-density lipoprotein-triglyceride production and/or intracellular lipid storage and signaling pathways because tissues are forced to increase nonoxidative FFA disposal. OBJECTIVE: The objective of the study was to examine whether variations in postabsorptive nonoxidative FFA disposal within the usual range predict insulin resistance and hypertriglyceridemia. DESIGN: We measured: systemic FFA turnover using a continuous iv infusion of [9-10, (3)H]palmitate; substrate oxidation with indirect calorimetry combined with urinary nitrogen excretion; whole-body and peripheral insulin sensitivity with the labeled iv glucose tolerance test minimal model. SETTING: the study was conducted at the Mayo Clinic General Clinical Research Center. PARTICIPANTS: Participants included healthy, postabsorptive, nonobese adults (21 women and 21 men). INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURES: Nonoxidative FFA disposal (micromoles per minute), defined as the FFA disappearance rate minus fatty acid oxidation. RESULTS: Women had 64% greater nonoxidative FFA disposal rate than men but a better lipid profile and similar insulin sensitivity. There was no significant correlation between nonoxidative FFA disposal and whole-body sensitivity, peripheral insulin sensitivity, or fasting serum triglyceride concentrations in men or women. CONCLUSIONS: Healthy nonobese women have greater rates of nonoxidative FFA disposal than men, but this does not appear to relate to adverse health consequences. Understanding the sex-specific interaction between adipose tissue lipolysis and peripheral FFA removal will help to discover new approaches to treat FFA-induced abnormalities.
CONTEXT: Large increases in systemic free fatty acid (FFA) availability in the absence of a corresponding increase in fatty acid oxidation can create a host of metabolic abnormalities. These adverse responses are thought to be the result of fatty acids being shunted into hepatic very low-density lipoprotein-triglyceride production and/or intracellular lipid storage and signaling pathways because tissues are forced to increase nonoxidative FFA disposal. OBJECTIVE: The objective of the study was to examine whether variations in postabsorptive nonoxidative FFA disposal within the usual range predict insulin resistance and hypertriglyceridemia. DESIGN: We measured: systemic FFA turnover using a continuous iv infusion of [9-10, (3)H]palmitate; substrate oxidation with indirect calorimetry combined with urinary nitrogen excretion; whole-body and peripheral insulin sensitivity with the labeled iv glucose tolerance test minimal model. SETTING: the study was conducted at the Mayo Clinic General Clinical Research Center. PARTICIPANTS: Participants included healthy, postabsorptive, nonobese adults (21 women and 21 men). INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURES: Nonoxidative FFA disposal (micromoles per minute), defined as the FFA disappearance rate minus fatty acid oxidation. RESULTS:Women had 64% greater nonoxidative FFA disposal rate than men but a better lipid profile and similar insulin sensitivity. There was no significant correlation between nonoxidative FFA disposal and whole-body sensitivity, peripheral insulin sensitivity, or fasting serum triglyceride concentrations in men or women. CONCLUSIONS: Healthy nonobese women have greater rates of nonoxidative FFA disposal than men, but this does not appear to relate to adverse health consequences. Understanding the sex-specific interaction between adipose tissue lipolysis and peripheral FFA removal will help to discover new approaches to treat FFA-induced abnormalities.
Authors: K Sreekumaran Nair; Robert A Rizza; Peter O'Brien; Ketan Dhatariya; Kevin R Short; Ajay Nehra; Janet L Vittone; George G Klee; Ananda Basu; Rita Basu; Claudio Cobelli; Gianna Toffolo; Chiara Dalla Man; Donald J Tindall; L Joseph Melton; Glenn E Smith; Sundeep Khosla; Michael D Jensen Journal: N Engl J Med Date: 2006-10-19 Impact factor: 91.245
Authors: A Dresner; D Laurent; M Marcucci; M E Griffin; S Dufour; G W Cline; L A Slezak; D K Andersen; R S Hundal; D L Rothman; K F Petersen; G I Shulman Journal: J Clin Invest Date: 1999-01 Impact factor: 14.808
Authors: Maria Morgan-Bathke; Liang Chen; Elisabeth Oberschneider; Debra Harteneck; Michael D Jensen Journal: Am J Physiol Endocrinol Metab Date: 2015-03-03 Impact factor: 4.310
Authors: Carson C Chow; Vipul Periwal; Gyorgy Csako; Madia Ricks; Amber B Courville; Bernard V Miller; Gloria L Vega; Anne E Sumner Journal: J Clin Endocrinol Metab Date: 2011-05-18 Impact factor: 5.958
Authors: Jordan A Levine; Jung Min Han; Anna Wolska; Sierra R Wilson; Tushar P Patel; Alan T Remaley; Vipul Periwal; Jack A Yanovski; Andrew P Demidowich Journal: J Clin Lipidol Date: 2020-08-04 Impact factor: 4.766
Authors: Diane C Adler-Wailes; Vipul Periwal; Asem H Ali; Sheila M Brady; Jennifer R McDuffie; Gabriel I Uwaifo; Marian Tanofsky-Kraff; Christine G Salaita; Van S Hubbard; James C Reynolds; Carson C Chow; Anne E Sumner; Jack A Yanovski Journal: J Clin Endocrinol Metab Date: 2013-02-28 Impact factor: 5.958